Literature DB >> 22134029

Intron 4 polymorphism of the endothelial nitric oxide synthase (eNOS) gene is associated with decreased NO production in a mercury-exposed population.

Katia Cristina de Marco1, Lusania Maria Greggi Antunes, Jose Eduardo Tanus-Santos, Fernando Barbosa.   

Abstract

Nitric oxide (NO), produced by endothelial nitric oxide synthase (eNOS), is a potent vasodilator and plays a prominent role in regulating the cardiovascular system. Decreased basal NO release may predispose to cardiovascular diseases. Evidence suggests that the 27 nt repeat polymorphism of the intron 4 in the eNOS gene may regulate eNOS expression. On the other hand, some recent reports strongly suggest an association between methylmercury (MeHg) exposures and altered NO synthesis. In the present study, we investigate the contribution of the 27-pb tandem repeat polymorphism on nitric oxide production, which could enhance susceptibility to cardiovascular disease in the MeHg-exposed study population. Two-hundred-two participants (98 men and 104 women), all chronically exposed to MeHg through fish consumption were examined. Mean blood Hg concentration and nitrite plasma concentration were 50.5 ± 35.4 μg/L and 251.4 ± 106.3n M, respectively. Mean systolic and diastolic blood pressure were 120.1 ± 19.4mm Hg and 72.0 ± 10.6mm Hg, respectively. Mean body mass index was 24.5 ± 4.3 kg/m(2) and the mean heart rate was 69.8 ± 11.8 bpm. There were no significant differences in age, arterial blood pressure, body mass index or cardiac frequency between genotype groups (all P>0.05). However, we observed different nitrite concentrations in the genotypes groups, with lower nitrite levels for the 4a4a genotype carriers. Age, gender and the presence of intron 4 polymorphism contributed to nitrite reduction as a result of blood Hg concentration. Taken together, our results show that the 27 nt repeat polymorphism of the intron 4 in the eNOS gene increases susceptibility to cardiovascular diseases after MeHg exposure by modulating nitric oxide levels.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22134029     DOI: 10.1016/j.scitotenv.2011.11.010

Source DB:  PubMed          Journal:  Sci Total Environ        ISSN: 0048-9697            Impact factor:   7.963


  6 in total

1.  Endothelial nitric oxide synthase gene polymorphism is associated with Legg-Calvé-Perthes disease.

Authors:  Yulong Zhao; Shijie Liao; Rongbin Lu; Hao Dang; Jinmin Zhao; Xiaofei Ding
Journal:  Exp Ther Med       Date:  2016-02-26       Impact factor: 2.447

2.  Recent Advances in Mercury Research.

Authors:  Ebany J Martinez-Finley; Michael Aschner
Journal:  Curr Environ Health Rep       Date:  2014-03-28

3.  Mechanisms and Modifiers of Methylmercury-Induced Neurotoxicity.

Authors:  Stephanie Jb Fretham; Samuel Caito; Ebany J Martinez-Finley; Michael Aschner
Journal:  Toxicol Res (Camb)       Date:  2012-05-02       Impact factor: 3.524

Review 4.  Genetic Aspects of Susceptibility to Mercury Toxicity: An Overview.

Authors:  Virginia Andreoli; Francesca Sprovieri
Journal:  Int J Environ Res Public Health       Date:  2017-01-18       Impact factor: 3.390

5.  Antioxidant Properties of Egg White Hydrolysate Prevent Mercury-Induced Vascular Damage in Resistance Arteries.

Authors:  Alyne Goulart Escobar; Danize Aparecida Rizzetti; Janaina Trindade Piagette; Franck Maciel Peçanha; Dalton Valentim Vassallo; Marta Miguel; Giulia Alessandra Wiggers
Journal:  Front Physiol       Date:  2020-11-20       Impact factor: 4.566

6.  Association of endothelial nitric oxide synthase (eNOS) gene polymorphisms and physical fitness levels with plasma nitrite concentrations and arterial blood pressure values in older adults.

Authors:  Roberta Fernanda da Silva; Átila Alexandre Trapé; Thaís Amanda Reia; Riccardo Lacchini; Gustavo Henrique Oliveira-Paula; Lucas Cezar Pinheiro; José Eduardo Tanus-Santos; André Mourão Jacomini; Carlos Roberto Bueno Júnior; Anderson Saranz Zago
Journal:  PLoS One       Date:  2018-10-18       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.